{
  "ticker": "JCS",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977661",
  "id": "02977661",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250806",
  "time": "1707",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06mlvs9nyldkch.pdf",
  "summary": "- **Key Director/Related Party Transactions**:  \n  - **Dr Philip Ewart**:  \n    - **Sales**: Multiple on-market sales totaling **739,426 shares** (Mar 2024 - Jun 2025). Largest single sale: **400,000 shares** (29/11/2024).  \n    - **Purchases**: **99,487 shares** acquired on-market (12/06/2025).  \n  - **Ewart Superannuation A/C**: Net **1,090,854 shares acquired** (Feb 2024 - Jun 2025). Largest single purchase: **400,000 shares** (29/11/2024).  \n  - **P Ewart Investments Pty Ltd**: Net **1,049,284 shares acquired** (Jan 2024 - Jan 2025).  \n\n- **Net Impact**:  \n  - Combined net **increase** in holdings by related entities (~**400,000 shares**, excluding minor transactions).  \n  - Significant sell-down by Dr Ewart personally (~**740k shares**), partially offset by purchases via related entities.  \n\n**Note**: No trading halt, capital raising, or financial data disclosed. Focus on director/insider activity.",
  "usage": {
    "prompt_tokens": 1955,
    "completion_tokens": 252,
    "total_tokens": 2207,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-06T08:05:48.548057"
}